. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2011 Jan 11;17(9):1308–1315. doi: 10.1016/j.bbmt.2011.01.004

Table 4.

Summary of Previous Reports of DLI without IL-2 Followed by Chemotherapy for Relapsed Acute Leukemia and Current Study

Parameters	Study
Parameters	Collins et al.[8]	Schmidt et al.[10]	Levine et al.[9]	Current
Design	Retrospective	Retrospective	Prospective	Prospective
Disease, no. of patients
Acute myeloid leukemia	7^*	124^*	50^*	11
Acute lymphoblastic leukemia	3^*	0	0	6
DLI dose, ×10⁸/kg CD3	2.2 (mean)^†	0.1 (median)^‡	1	1
Grades II–IV acute GVHD	46%^†	34%^‡	45%§	35%
Grades III–IV acute GVHD	22%^†	NA	28%§	29%
Chronic GVHD	61%^†	46%^‡	36%§	64%
Chronic extensive GVHD	32%^†	26%^‡	14%§	50%
1 year DFS after DLI	54% in AML 33% in ALL	NA	34% among patients in CR at DLI^§	40% in AML CR at DLI, 8.3% in others

DLI indicates donor lymphocyte infusion; GVHD, graft-versus-host disease; NA, not assessable; DFS, disease-free survival; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CR, complete remission.

Data abstracted from the entire cohort.

^†

Data represent the entire study cohort of 140 patients treated for various diagnoses and irrespective of the presence of chemotherapy before DLI.

^‡

Data represent the entire study cohort of 171 AML patients. Of the 171 patients, 124 received chemotherapy before DLI and information was missing in 7 patients.

^§

Data represent the entire study cohort of 65 patients including 50 with AML and 15 with other diagnoses.